Literature DB >> 8811149

Effect of syringe size on bruising following subcutaneous heparin injection.

S A Hadley1, M Chang, K Rogers.   

Abstract

BACKGROUND: Bruising and induration associated with subcutaneous heparin injection often result in sustained tenderness and severe ecchymosis at the injection site. Research-based practice guidelines for subcutaneous heparin administration are needed to reduce these adverse effects.
OBJECTIVES: The purpose of this study was to investigate the effect of syringe size (1-mL vs 3-mL) on postinjection-site bruising and induration following the administration of subcutaneous heparin.
METHODS: A convenience sample of 29 subjects receiving 5000 units of subcutaneous heparin at least twice a day was recruited from a large urban hospital. Subjects received their regularly scheduled subcutaneous heparin injections with a 3-mL or a 1-mL syringe in a randomized sequence using a standardized procedure. Injection sites were assessed for bruises and induration at 24, 48, and 72 hours after injection.
RESULTS: The incidence of injection site bruising with 1- and 3-mL syringes was 79% and 69%, respectively. The use of a 3-mL vs 1-mL syringe resulted in significantly smaller bruises at 48 and 72 hours after injection. Induration at the injection site occurred in three patients.
CONCLUSIONS: Findings suggest that 3-mL syringes are preferable to 1-mL syringes for heparin administration. The effect of other injection-related variables should be studied with the use of the 3-mL syringe, and tested on various populations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8811149

Source DB:  PubMed          Journal:  Am J Crit Care        ISSN: 1062-3264            Impact factor:   2.228


  6 in total

Review 1.  Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity.

Authors:  Mina Mohammady; Leila Janani; Ali Akbari Sari
Journal:  Cochrane Database Syst Rev       Date:  2017-11-01

Review 2.  Long-term use of daily subcutaneous low molecular weight heparin in cancer patients with venous thromboembolism: why hesitate any longer?

Authors:  Philippe Debourdeau; Ismail Elalamy; Axelle de Raignac; Paul Meria; Jean Marc Gornet; Yahovi Amah; Wolfang Korte; Michel Marty; Dominique Farge
Journal:  Support Care Cancer       Date:  2008-08-15       Impact factor: 3.603

3.  Effect of a direct thrombin inhibitor compared with dalteparin and unfractionated heparin on human osteoblasts.

Authors:  Tobias Winkler; Carsten Perka; Dörte Matziolis; Georg Matziolis
Journal:  Open Orthop J       Date:  2011-03-16

4.  [Perioperative Venous Thromboembolism (VTE) Prophylaxis in Thoracic Cancer Patients: Chinese Experts Consensus - Interpretation of Application Prospect of Direct Oral Anticoagulant].

Authors:  Ruiheng Jiang; Tong Li; Hui Li
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-12-20

Review 5.  Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity.

Authors:  Mina Mohammady; Leila Janani; Ali Akbari Sari
Journal:  Cochrane Database Syst Rev       Date:  2017-10-01

6.  Quality of life in cancer patients undergoing anticoagulant treatment with LMWH for venous thromboembolism: the QUAVITEC study on behalf of the Groupe Francophone Thrombose et Cancer (GFTC).

Authors:  Dominique Farge; Francis Cajfinger; Nicolas Falvo; Toufek Berremili; Francis Couturaud; Okba Bensaoula; Lionel Védrine; Hocine Bensalha; Isabelle Bonnet; Denis Péré-Vergé; Marie Coudurier; Veronique Li; Hanadi Rafii; Ilham Benzidia; Jean M Connors; Matthieu Resche-Rigon
Journal:  Oncotarget       Date:  2018-06-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.